Skip to content

Public FDA record

Z-1951-2021: LEGION Posterior Stabilized OXINIUM Femoral Component, REF 71421216, Size 6, Left, Nonporous Femoral Comp

Recall record Z-1951-2021 for Smith & Nephew, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1951-2021
Company in FDA record
Smith & Nephew, Inc.
FDA record creation date
Jun 24, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

The device components experienced a manufacturing process error that resulted in surface damage from product handling.

Source facts

Action
On 5/19/2021, the firm issued letters dated 5/19/2021 via overnight mail or via email explaining the issue, potential risk of use of the product, and required actions, which are listed on the response form.
Initiated
2021-05-19
Root cause
Nonconforming Material/Component
Terminated
2023-04-14
Distribution
US Nationwide distribution in the states of FL, NE, NY, and TX. There was no foreign/government/military distribution.
Recall number
Z-1951-2021
Recall status
Terminated
CDRH record ID
187669
FDA record created
2021-06-24
Recall event number
88010

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗